ATLANTA, Sept. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the upcoming UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City.
D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Wednesday, September 24 at 2:30 p.m., Eastern Time.
CryoLife's live presentation may be accessed through its Web site, http://www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available until October 25, 2008 on the same Web site.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany and France for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.
For additional information about the Company, visit CryoLife's Web
Site: http://www.cryolife.com .
D. Ashley Lee
Executive Vice President, Chief Financial Officer and
Chief Operating Officer
|SOURCE CryoLife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved